Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings—one-third of which was for men in the over 75 age group, according to study by researchers at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center.
Published in the Oct. 4 issue of the journal Cancer, the study also found considerable geographic variation in the cost of prostate cancer screening.
Many prostate cancers are slow-growing and unlikely to become problematic. Widespread screening with a serum-based PSA test may result in unnecessary invasive biopsies, which can be a physical burden or even harmful. In 2012, the U.S. Preventative Services Task Force decided to stop recommending PSA screening for men of any age. Medicare, however, continues to reimburse for this test and the subsequent procedures.
Lead author Xiaomei Ma, associate professor at Yale School of Public Health, and her Yale COPPER Center colleagues conducted an observational study of older male Medicare beneficiaries who were free of prostate cancer and other lower urinary tract symptoms at the end of 2006, and followed them for three years.
In addition to large Medicare spending for prostate cancer screening in older men, the team found that the costs of prostate cancer screening ranged considerably from $17 to $62 per beneficiary across regions. The bulk of this variation was not due to the cost of PSA test itself, but rather to variation in costs of the follow-up tests across regions.
"More than 70% of prostate cancer screening-related costs were due to follow-up procedures," said Ma, who is also a member of the Yale Cancer Center. "Our results suggest that the overall cost of prostate cancer screening may be heavily influenced by how urologists choose to respond to the result of a PSA test, more so than the use of the PSA itself."
Meanwhile, the benefits of screening and treatment are not clear. While men living in high-spending regions were more likely to be diagnosed with localized cancers, they were not significantly less likely to be diagnosed with metastatic cancer. This suggests that spending more on prostate cancer screening might identify more localized tumors, but may not necessarily reduce the rate of metastatic cancers.
"In terms of what these results mean for Medicare spending, this is just the tip of the iceberg," said Cary Gross, M.D., professor of internal medicine at Yale School of Medicine, and director of the Yale COPPER Center. "Many older men who are diagnosed with early-stage prostate cancer may end up receiving therapy that is potentially toxic, has little chance of benefit, and carries substantial cost. In order to truly understand the costs of screening, the next step is to identify how many additional cancers are being diagnosed and treated as a result of screening older men for prostate cancer. We need better tools to target screening efforts towards those who are likely to benefit."
"In a time when healthcare spending is soaring, it is important to weigh the physical, psychological, and financial burden of cancer screening against the possible clinical benefit," said Gross, who is a member of the Yale Cancer Center. "The cancer research community needs to continue exploring novel approaches to target prostate cancer screening and treatment efforts, identifying and disseminating strategies that work, and abandoning strategies that don't work."
Explore further: Organized screening for prostate cancer does more harm than good
More information: Cancer, DOI: 10.1002/cncr.28373 (Oct. 4, 2013)
Medical Xpress on facebook
Related Stories
Organized screening for prostate cancer does more harm than good
Sep 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...
New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer
Sep 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
Costly breast cancer screenings don't add up to better outcomes
Jan 07, 2013
Even though Medicare spends over $1 billion per year on breast cancer screenings such as a mammography, there is no evidence that higher spending benefits older women, researchers at Yale School of Medicine found in a study ...
Alternative PSA screening strategies could reduce harm
Feb 05, 2013
(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary ...
Personalised prostate cancer screening may save thousands from unnecessary treatment
Nov 05, 2012
Targeting prostate cancer screening based on a man's age and genes could potentially save thousands of men from unnecessary treatment and save the NHS millions of pounds. The research is presented at the NCRI ...
Recommended for you
Molecular imaging predicts risk for abdominal aortic aneurysms
7 hours ago
Several newly identified markers could provide valuable insight to predict the risk of rupture abdominal aortic aneurysms (AAA), according to new research published in the October issue of the Journal of Nuclear Medicine. Imagin ...
Old remedy shows promise as new chemo drug for bladder cancer
10 hours ago
An old home remedy called ipecac syrup, once stocked in medicine cabinets in case of accidental poisoning, is showing promise as a new chemotherapy drug for bladder cancer.
Triple-negative breast cancer target for drug development identified
11 hours ago
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described ...
Can eating watercress help fight breast cancer?
15 hours ago
The University of Reading is playing a leading role in a new study which will examine the effects of eating watercress on breast cancer patients.
'Critical gaps' in breast cancer research
17 hours ago
Critical gaps in breast cancer research could see the loss of around 185,000* lives by 2030 if they are not urgently addressed, according to a major new study co-authored by researchers from King's College ...
New pain-free treatment for prostate cancer? Not quite
17 hours ago
If you or someone close to you has lived with prostate cancer, you've probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the "new ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings—one-third of which was for men in the over 75 age group, according to study by researchers at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center.
Published in the Oct. 4 issue of the journal Cancer, the study also found considerable geographic variation in the cost of prostate cancer screening.
Many prostate cancers are slow-growing and unlikely to become problematic. Widespread screening with a serum-based PSA test may result in unnecessary invasive biopsies, which can be a physical burden or even harmful. In 2012, the U.S. Preventative Services Task Force decided to stop recommending PSA screening for men of any age. Medicare, however, continues to reimburse for this test and the subsequent procedures.
Lead author Xiaomei Ma, associate professor at Yale School of Public Health, and her Yale COPPER Center colleagues conducted an observational study of older male Medicare beneficiaries who were free of prostate cancer and other lower urinary tract symptoms at the end of 2006, and followed them for three years.
In addition to large Medicare spending for prostate cancer screening in older men, the team found that the costs of prostate cancer screening ranged considerably from $17 to $62 per beneficiary across regions. The bulk of this variation was not due to the cost of PSA test itself, but rather to variation in costs of the follow-up tests across regions.
"More than 70% of prostate cancer screening-related costs were due to follow-up procedures," said Ma, who is also a member of the Yale Cancer Center. "Our results suggest that the overall cost of prostate cancer screening may be heavily influenced by how urologists choose to respond to the result of a PSA test, more so than the use of the PSA itself."
Meanwhile, the benefits of screening and treatment are not clear. While men living in high-spending regions were more likely to be diagnosed with localized cancers, they were not significantly less likely to be diagnosed with metastatic cancer. This suggests that spending more on prostate cancer screening might identify more localized tumors, but may not necessarily reduce the rate of metastatic cancers.
"In terms of what these results mean for Medicare spending, this is just the tip of the iceberg," said Cary Gross, M.D., professor of internal medicine at Yale School of Medicine, and director of the Yale COPPER Center. "Many older men who are diagnosed with early-stage prostate cancer may end up receiving therapy that is potentially toxic, has little chance of benefit, and carries substantial cost. In order to truly understand the costs of screening, the next step is to identify how many additional cancers are being diagnosed and treated as a result of screening older men for prostate cancer. We need better tools to target screening efforts towards those who are likely to benefit."
"In a time when healthcare spending is soaring, it is important to weigh the physical, psychological, and financial burden of cancer screening against the possible clinical benefit," said Gross, who is a member of the Yale Cancer Center. "The cancer research community needs to continue exploring novel approaches to target prostate cancer screening and treatment efforts, identifying and disseminating strategies that work, and abandoning strategies that don't work."
Explore further: Organized screening for prostate cancer does more harm than good
More information: Cancer, DOI: 10.1002/cncr.28373 (Oct. 4, 2013)
Medical Xpress on facebook
Related Stories
Organized screening for prostate cancer does more harm than good
Sep 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...
New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer
Sep 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
Costly breast cancer screenings don't add up to better outcomes
Jan 07, 2013
Even though Medicare spends over $1 billion per year on breast cancer screenings such as a mammography, there is no evidence that higher spending benefits older women, researchers at Yale School of Medicine found in a study ...
Alternative PSA screening strategies could reduce harm
Feb 05, 2013
(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary ...
Personalised prostate cancer screening may save thousands from unnecessary treatment
Nov 05, 2012
Targeting prostate cancer screening based on a man's age and genes could potentially save thousands of men from unnecessary treatment and save the NHS millions of pounds. The research is presented at the NCRI ...
Recommended for you
Molecular imaging predicts risk for abdominal aortic aneurysms
7 hours ago
Several newly identified markers could provide valuable insight to predict the risk of rupture abdominal aortic aneurysms (AAA), according to new research published in the October issue of the Journal of Nuclear Medicine. Imagin ...
Old remedy shows promise as new chemo drug for bladder cancer
10 hours ago
An old home remedy called ipecac syrup, once stocked in medicine cabinets in case of accidental poisoning, is showing promise as a new chemotherapy drug for bladder cancer.
Triple-negative breast cancer target for drug development identified
11 hours ago
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described ...
Can eating watercress help fight breast cancer?
15 hours ago
The University of Reading is playing a leading role in a new study which will examine the effects of eating watercress on breast cancer patients.
'Critical gaps' in breast cancer research
17 hours ago
Critical gaps in breast cancer research could see the loss of around 185,000* lives by 2030 if they are not urgently addressed, according to a major new study co-authored by researchers from King's College ...
New pain-free treatment for prostate cancer? Not quite
17 hours ago
If you or someone close to you has lived with prostate cancer, you've probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the "new ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment